Growth Metrics

Palisade Bio (PALI) Operating Leases (2019 - 2024)

Palisade Bio (PALI) reported Operating Leases of $24000.0 for Q2 2024, down 84.31% year-over-year from $153000.0 in Q3 2023, and down 58.62% on a QoQ basis from $58000.0 in Q1 2024.

Palisade Bio (PALI) has 6 years of Operating Leases data on file, last reported at $24000.0 in Q2 2024.

  • Quarterly Operating Leases fell 84.31% year-over-year to $24000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $24000.0 (down 84.31% YoY) and the FY2023 annual result came in at $90000.0, down 57.35% from the prior year.
  • Operating Leases retreated to $24000.0 in Q2 2024 per PALI's latest filing, from $58000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $364000.0 in Q2 2022 and bottomed at $17000.0 in Q2 2021.
  • The 5-year median for Operating Leases is $136395.0 (2020), against an average of $143637.7.
  • The widest annual swing landed in 2021, when Operating Leases sank 86.8%; it then soared 2041.18% in 2022.
  • Tracing PALI's Operating Leases over 5 years: stood at $112000.0 in 2020, then soared by 41.07% to $158000.0 in 2021, then surged by 33.54% to $211000.0 in 2022, then sank by 57.35% to $90000.0 in 2023, then sank by 73.33% to $24000.0 in 2024.
  • Per Business Quant, the three latest PALI Operating Leases figures stand at $24000.0 (Q2 2024), $58000.0 (Q1 2024), and $90000.0 (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Palisade Bio 439.25 Mn 309.68 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 24,000.00
Mar 31, 2024 58,000.00
Dec 31, 2023 90,000.00
Sep 30, 2023 122,000.00
Jun 30, 2023 153,000.00
Mar 31, 2023 182,000.00
Dec 31, 2022 211,000.00
Sep 30, 2022 239,000.00
Jun 30, 2022 364,000.00
Sep 30, 2021 158,000.00
Jun 30, 2021 17,000.00
Dec 31, 2020 112,000.00
Sep 30, 2020 159,400.00
Jun 30, 2020 128,770.00
Mar 31, 2020 136,395.00
Dec 31, 2019 148,543.00
Sep 30, 2019 183,520.00